Severe Anemia Due to Parvovirus Infection Following Treatment with Rituximab in a Pediatric Kidney Transplant Recipient : Anemia after Treatment of Rituximab in Kidney Recipient Patient
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Rituximab (RTX), a monoclonal antibody against the B-cell marker CD20, is commonly used as a treatment for antibody-mediated diseases or B-lymphocytemediated diseases. Destruction of B cells may reverse the disease course in many conditions; however, patients who are treated with RTX cannot respond appropriately to de novo infection due to lack of B lymphocytes. Here, we report one such case. A 7-year-old renal allograft recipient presented with severe anemia due to parvovirus infection after RTX treatment. The patient had focal segmental glomerulosclerosis and had received cadaveric kidney transplantation 6 months previously. She was treated with high-dose steroid for acute rejection and RTX for Epstein Barr Virus infection 3 months previously. At presentation, her hemoglobin level was 5.4 g/dL and leukocyte and platelet counts were normal. She had microcytic normochromic anemia and high viral load of parvovirus B19(70,578 copies/mL). Intravenous immunoglobulin (200 mg/kg·d) treatment controlled the progression of anemia and parvovirus infection. De novo parvovirus infection during the B lymphocyte-depletion period may have precipitated the severe anemia in this case. Close monitoring of infection is required after RTX therapy.
Abstract
Rituximab (RTX), a monoclonal antibody against the B-cell marker CD20, is commonly used as a treatment for antibody-mediated diseases or B-lymphocytemediated diseases. Destruction of B cells may reverse the disease course in many conditions; however, patients who are treated with RTX cannot respond appropriately to de novo infection due to lack of B lymphocytes. Here, we report one such case. A 7-year-old renal allograft recipient presented with severe anemia due to parvovirus infection after RTX treatment. The patient had focal segmental glomerulosclerosis and had received cadaveric kidney transplantation 6 months previously. She was treated with high-dose steroid for acute rejection and RTX for Epstein Barr Virus infection 3 months previously. At presentation, her hemoglobin level was 5.4 g/dL and leukocyte and platelet counts were normal. She had microcytic normochromic anemia and high viral load of parvovirus B19(70,578 copies/mL). Intravenous immunoglobulin (200 mg/kg·d) treatment controlled the progression of anemia and parvovirus infection. De novo parvovirus infection during the B lymphocyte-depletion period may have precipitated the severe anemia in this case. Close monitoring of infection is required after RTX therapy.
참고문헌 (12)
- 김성도, "소아 신이식의 최신 지견", Korean Journal of Pediatrics, 52(10), pp.1075~1081 (2009), 대한소아과학회
- "NAPRTCS 2010 Annual Transplant Report" (2013)[URL]
- Comoli P, "Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation", Am J Transplant, 7, pp.1648~1655 (2007)
- Sawada K, "Acquired pure red cell aplasia: updated review of treatment", Br J Haematol, 142, pp.505~514 (2008)
- Liang TB, "Pure red cell aplasia due to parvovirus B19 infection after liver transplantation:a case report and review of the literature", World J Gastroenterol, 13, pp.2007~2010 (2007)
- Tsirigotis P, "Pure Red Cell Aplasia due to B19Parvovirus Infection after Autologous Stem Cell Transplantation", Case Rep Transplant, 2011, pp.251930~ (2011)
- Koduri PR, "Parvovirus B19-related anemia in HIV-infected patients", AIDS Patient Care STDS, 14, pp.7~11 (2000)
- Mathias RS, "Chronic anemia as a complication of parvovirus B19infection in a pediatric kidney transplant patient", Pediatr Nephrol, 11, pp.355~357 (1997)
- Gea-Banacloche JC, "Rituximab-associated infections", Semin Hematol, 47, pp.187~198 (2010)
- Sharma VR, "Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab", Blood, 96, pp.1184~1186 (2000)
- Song KW, "Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma", Br J Haematol, 119, pp.125~127 (2002)
- Becker YT, "The emerging role of rituximab in organ transplantation", Transpl Int, 19, pp.621~628 (2006)